"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the ...

The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or ...

Daiichi Sankyo’s DS3610 enters clinical development in patients with advanced solid tumours: Tokyo Wednesday, November 12, 2025, 11:00 Hrs [IST] Daiichi Sankyo, an innovative gl ...

U.S. net product revenue for the three and nine months ended September 30, 2025 was $40.7 million and $115.8 million, respectively, compared to $31.1 million and $84.2 million, for the comparable ...

Q3 2025 Earnings Call Transcript November 6, 2025 Esperion Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

The endometrial cancer market space will experience significant growth during the forecast period of 2025--2034. The future is brighter for patients with endometrial cancer. Targeted agents and ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Uniting The Global Biopharma Community In Suzhou. Suzhou, China – March 12–14, 2026, The global biopharmaceutical industry ...

– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Rapid Micro Biosystems, Inc. (NASDAQ: RPID) Q3 2025 Earnings Call Transcript November 7, 2025 Rapid Micro Biosystems, Inc.

AstraZeneca’s AZN third-quarter 2025 core earnings of $1.19 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.14 per share. Core earnings of $2.38 per share rose 14% year ...